About Us

---

Hinge Bio, Inc. is leveraging its proprietary Flex-Hinge antibody platform to develop the next-generation of bispecific and multispecific antibodies that bind with multi-handed cooperativity to both disease targets and effector cells. Hinge Bio’s streamlined chemical ligation process technology enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity, incorporating virtually any polypeptide, including gold standard targeting domains such as natural, unmodified Fabs, and effector molecules including agonists, cytokines, growth factors and receptor decoys.